On July 3, 2025, Ashley Hinson voted for the One Big Beautiful Bill Act, which exempts more drugs from Medicare price negotiation and costs Medicare an additional $8.8 billion, according to the Congressional Budget Office.
In 2022, Hinson voted against a $35 monthly insulin cap for people with private insurance, which never became law, and against the Inflation Reduction Act, the law that lets Medicare negotiate drug prices.
Ashley Hinson's Votes on Drug Prices and Insulin
- Hinson Voted to Exempt More Drugs From Medicare Price Negotiation in July 2025. On July 3, 2025, Ashley Hinson voted for final passage of H.R. 1, the One Big Beautiful Bill Act, which passed 218 to 214. Its section 71203 widens the exemption for orphan drugs, those approved for rare diseases, from Medicare drug price negotiation. The Congressional Budget Office estimates the change costs Medicare an additional $8.8 billion, and it allows the program to delay selection of Keytruda and Opdivo, two cancer drugs on which Medicare and beneficiaries spent $5.6 billion on Keytruda alone in 2023.
- Hinson Voted Against a $35 Insulin Cap for People With Private Insurance in 2022. On March 31, 2022, Hinson voted against the Affordable Insulin Now Act, which passed 232 to 193 with 12 Republican votes. It required that a group health plan or health insurance issuer offering group or individual health insurance coverage shall provide coverage of selected insulin products without a deductible and capped what patients pay at $35 per 30-day supply. The bill never became law, and four years later people with private insurance still had no federal cap: in July 2026 the Senate was considering a bill that would cap the cost of insulin at $35 per month for people on private insurance, and in September 2026 Iowa Rep. Mariannette Miller-Meeks was still pushing legislation that caps out-of-pocket insulin costs at $35 a month for Americans on private insurance.
- Hinson Voted Against Medicare Drug Price Negotiation and the Medicare Insulin Cap in 2022. On August 12, 2022, Hinson voted against the Inflation Reduction Act, which passed 220 to 207 with no Republican votes. The law lets Medicare negotiate prices for some drugs and one of its provisions is to limit monthly cost sharing for insulin to $35 for people with Medicare. Her position runs against the public: in a 2026 KFF poll, 85% of the public supported allowing the federal government to negotiate lower prices for people with Medicare. CMS estimated that the first ten negotiated prices mean Medicare beneficiaries will save $1.5 billion when these negotiated prices take effect in 2026.
What Ashley Hinson's Drug-Price Votes Mean for Iowa
- Medicare drug coverage. In Iowa, 685,807 people are enrolled in Medicare, according to recent KFF data; they are the people for whom negotiated prices and the orphan-drug exemption matter.
Frequently Asked Questions About Ashley Hinson on Prescription drugs
What is Ashley Hinson's record on prescription drug prices under Trump?
Ashley Hinson voted for the One Big Beautiful Bill Act, which exempts more drugs from Medicare price negotiation. Before Trump's second term, in 2022, she voted against the Affordable Insulin Now Act and the Inflation Reduction Act, the law that created Medicare drug price negotiation. In a 2026 KFF poll, 72% of adults said there is not enough government regulation of prescription drug prices.
Did Ashley Hinson vote for the $35 insulin cap?
No. Ashley Hinson voted against the Affordable Insulin Now Act on March 31, 2022, which would have capped insulin at $35 a month for people with private insurance, and against the Inflation Reduction Act on August 12, 2022, the law that set the $35 cap for people with Medicare. A cap for people with private insurance was still under consideration in the Senate in July 2026.
Why were Keytruda and Opdivo left out of Medicare drug price negotiation?
The law Ashley Hinson voted for on July 3, 2025 widened the orphan-drug exemption, which KFF says will delay selection of Keytruda and Opdivo for negotiation. KFF estimated a Keytruda user would have seen annual savings on cost-sharing liability of around $3,300.
Last updated: 2026-10-25